NCT04889495View on ClinicalTrials.gov

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

WithdrawnOBSERVATIONAL

Timeline

Start Date

May 16, 2025

Primary Completion Date

August 16, 2025

Study Completion Date

August 16, 2025

Conditions

Non-small Cell Lung CancerMetastatic Colorectal CancerMetastatic Breast CancerMetastatic Kidney CancerCervical CancerEpithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Interventions

DRUG

Zirabev

Bevacizumab biosimilar